SOCS-1 and SOCS-3 Inhibit IL-4 and IL-13 Induced Activation of Eotaxin-3/CCL26 Gene Expression in HEK293 Cells
Overview
Molecular Biology
Affiliations
Secretion of various chemokines including Eotaxin-3/CCL26 results in the attraction of eosinophils to sites of allergic inflammation. IL-4/IL-13-induced activation of the Eotaxin-3/CCL26 gene in human dermal fibroblasts was shown to be a STAT6-dependent process mediated by a single STAT6 binding motif located upstream of the transcription initiation site. The suppressors of cytokine signaling 1-3 (SOCS 1-3) are members of a recently discovered family of proteins acting as negative regulators of cytokine signaling. We show here, that transfection of SOCS-1 and SOCS-3 but not SOCS-2 expression vectors inhibited IL-4/IL-13 induced secretion of Eotaxin-3/CCL26. Further, using Eotaxin-3/CCL26 promoter reporter gene constructs, we could show that, upon cotransfection of SOCS-1 and SOCS-3 expression vectors, IL-4 and IL-13 induced luciferase activity was strongly reduced. This effect was not seen when SOCS-2 was cotransfected. Further, EMSA studies with nuclear extracts prepared from IL-4/IL-13 induced HEK293 cells were conducted. The nuclear extracts of cells transfected with SOCS-1 or SOCS-3 did not form complexes with oligonucleotide probes corresponding to the STAT6 binding site in the Eotaxin-3/CCL26 promoter. In contrast, complex formation upon SOCS-2-transfection was comparable to mock-transfected cells. Further, the levels of phosphorylated STAT6 in IL-4 and IL-13 treated cells were markedly reduced when the cells had been transfected with SOCS-1 or SOCS-3, confirming the role of these negative regulators for the IL-4 and IL-13 induced activation of Eotaxin-3/CCL26 gene expression. The insertion of amino acid exchanges into the kinase inhibitory regions of SOCS-1 and SOCS-3 demonstrated a requirement of these domains for a proper inhibitory function.
Systematic identification of genotype-dependent enhancer variants in eosinophilic esophagitis.
Shook M, Lu X, Chen X, Parameswaran S, Edsall L, Trimarchi M Am J Hum Genet. 2024; 111(2):280-294.
PMID: 38183988 PMC: 10870143. DOI: 10.1016/j.ajhg.2023.12.008.
Marella S, Sharma A, Ganesan V, Ferrer-Torres D, Krempski J, Idelman G J Allergy Clin Immunol. 2023; 152(6):1550-1568.
PMID: 37652141 PMC: 11102758. DOI: 10.1016/j.jaci.2023.07.021.
AMPK suppresses Th2 cell responses by repressing mTORC2.
Pandit M, Timilshina M, Gu Y, Acharya S, Chung Y, Seo S Exp Mol Med. 2022; 54(8):1214-1224.
PMID: 35999454 PMC: 9440126. DOI: 10.1038/s12276-022-00832-x.
Modulation of IL-4/IL-13 cytokine signaling in the context of allergic disease.
Shankar A, McAlees J, Lewkowich I J Allergy Clin Immunol. 2022; 150(2):266-276.
PMID: 35934680 PMC: 9371363. DOI: 10.1016/j.jaci.2022.06.012.
Wheeler J, Vanoni S, Zeng C, Waggoner L, Yang Y, Wu D J Allergy Clin Immunol. 2018; 143(6):2131-2146.
PMID: 30578870 PMC: 6556402. DOI: 10.1016/j.jaci.2018.10.070.